Orchestra BioMed (NASDAQ:OBIO) Raised to Hold at Wall Street Zen

Orchestra BioMed (NASDAQ:OBIO) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a report issued on Saturday.

A number of other equities research analysts also recently weighed in on the company. Barclays boosted their price target on Orchestra BioMed from $11.00 to $12.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Chardan Capital restated a “buy” rating and set a $20.00 price objective on shares of Orchestra BioMed in a research note on Thursday. Finally, TD Cowen started coverage on shares of Orchestra BioMed in a report on Wednesday, December 10th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Orchestra BioMed has an average rating of “Moderate Buy” and a consensus price target of $13.80.

Orchestra BioMed Stock Down 4.1%

NASDAQ:OBIO opened at $4.20 on Friday. The company has a market capitalization of $245.78 million, a price-to-earnings ratio of -3.72 and a beta of 0.56. Orchestra BioMed has a one year low of $2.20 and a one year high of $5.42. The stock has a 50-day simple moving average of $4.19 and a 200 day simple moving average of $3.86. The company has a debt-to-equity ratio of 0.27, a quick ratio of 6.43 and a current ratio of 6.45.

Orchestra BioMed (NASDAQ:OBIO) last announced its quarterly earnings data on Thursday, March 12th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.64. Orchestra BioMed had a negative return on equity of 184.17% and a negative net margin of 157.40%.The firm had revenue of $30.92 million for the quarter, compared to analysts’ expectations of $0.93 million. Sell-side analysts predict that Orchestra BioMed will post -1.66 EPS for the current fiscal year.

Hedge Funds Weigh In On Orchestra BioMed

Institutional investors have recently made changes to their positions in the stock. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Orchestra BioMed during the 2nd quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. acquired a new position in Orchestra BioMed during the 4th quarter valued at approximately $38,000. Creative Planning acquired a new position in Orchestra BioMed during the 2nd quarter valued at approximately $40,000. XTX Topco Ltd bought a new position in Orchestra BioMed during the 2nd quarter worth $45,000. Finally, Jane Street Group LLC bought a new position in Orchestra BioMed during the 2nd quarter worth $50,000. 53.20% of the stock is owned by institutional investors.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.